Accumulating evidence indicates that CSF levels of p-tau change earlier than the tau PET signal in preclinical AD (208), reaching a relative plateau during the symptomatic stage of the disease (209,210), whereas the tau PET signal continues to increase in patients with AD dementia (211). The gene discussed is MAPT; the disease is dementia.